We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk

By LabMedica International staff writers
Posted on 23 Jul 2026

Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death and often affects otherwise fit individuals. Cardiomyopathies can arise from DNA changes that alter essential heart proteins, yet determining whether a specific change is responsible for disease remains difficult for patients and families. Clearer functional evidence can strengthen variant interpretation in clinical genetics. 

University of Birmingham investigators, working with colleagues at the University of Oxford and Research Campus Harwell, conducted comprehensive biophysical and structural profiling of 17 ACTN2 sequence variants linked to hypertrophic cardiomyopathy (HCM) and assessed their molecular consequences. The analysis identified multiple variant-specific disruptions to alpha-actinin-2, including reduced protein stability, a greater tendency to clump, and weakened interactions with other molecules. The work positions this profiling strategy as a systematic approach for interrogating ACTN2-associated disease mechanisms.


Image Credit: Adobe Stock
Image Credit: Adobe Stock

The team reports that the effects of these genetic changes depend on their location within the protein. One notable hotspot was the Actin Binding Domain (ABD), a critical region that enables alpha-actinin-2 to interact with other cellular components involved in major cellular processes. By mapping consequences across domains, the study delineates a mechanistic spectrum that can inform how individual variants are interpreted in a diagnostic context.

Published in Nature Communications on July 21, 2026, the research outlines a framework the authors describe as readily reproducible in other laboratories. According to the study, this approach may help interpret genetic test results for ACTN2-associated cardiomyopathies and could be adapted to evaluate disease-causing changes in other heart proteins. The project highlights the value of interdisciplinary collaboration and forms part of broader investigations into HCM and related inherited heart conditions.

“Several of the experimental approaches used in this study are readily reproducible in other laboratories. We hope this framework will improve the interpretation of genetic test results for ACTN2-associated cardiomyopathies and could be adapted to study disease-causing genetic changes in other heart proteins,” stated Dr. Fiyaz Mohammed, corresponding author and Lecturer at the University of Birmingham.

“Hypertrophic cardiomyopathy often affects otherwise fit and healthy individuals, and the effects of the condition can be devastating, as seen in the cases of high-profile footballers such as Mark-Vivian Foe who sadly died in competition. The findings will help us and other researchers worldwide to find potential ways to address these genetic weaknesses and better understand how these proteins are literally reshaping the hearts of people with this condition,” said Katja Gehmlich, Professor of Molecular Cardiology at the University of Birmingham.

Related Links
University of Birmingham


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
HPV Test
Allplex HPV28 Detection

Latest BioResearch News

Immune Biomarkers Support Early Risk Stratification in Oral Precancer
22 Jul 2026  |   BioResearch

Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
22 Jul 2026  |   BioResearch

Breakthrough Genetic Map Advances Understanding of Bone Disorders
22 Jul 2026  |   BioResearch



PURITAN MEDICAL